ATE225349T1 - Crf rezeptor-antagonisten und darauf bezogene methoden - Google Patents

Crf rezeptor-antagonisten und darauf bezogene methoden

Info

Publication number
ATE225349T1
ATE225349T1 AT99960363T AT99960363T ATE225349T1 AT E225349 T1 ATE225349 T1 AT E225349T1 AT 99960363 T AT99960363 T AT 99960363T AT 99960363 T AT99960363 T AT 99960363T AT E225349 T1 ATE225349 T1 AT E225349T1
Authority
AT
Austria
Prior art keywords
crf receptor
receptor antagonists
related methods
crf
pharmaceutically acceptable
Prior art date
Application number
AT99960363T
Other languages
German (de)
English (en)
Inventor
Mustapha Haddach
Jodie Nelson
Brian P Dyck
Zhiqiang Guo
Charles Q Huang
James R Mccarthy
Original Assignee
Neurocrine Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurocrine Biosciences Inc filed Critical Neurocrine Biosciences Inc
Application granted granted Critical
Publication of ATE225349T1 publication Critical patent/ATE225349T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/16—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/16—Peri-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Pulse, Heart Rate, Blood Pressure Or Blood Flow (AREA)
  • Input Circuits Of Receivers And Coupling Of Receivers And Audio Equipment (AREA)
AT99960363T 1998-11-12 1999-11-12 Crf rezeptor-antagonisten und darauf bezogene methoden ATE225349T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US19107398A 1998-11-12 1998-11-12
US37083799A 1999-08-09 1999-08-09
US40136499A 1999-09-21 1999-09-21
PCT/US1999/027054 WO2000027846A2 (en) 1998-11-12 1999-11-12 Crf receptor antagonists and methods relating thereto

Publications (1)

Publication Number Publication Date
ATE225349T1 true ATE225349T1 (de) 2002-10-15

Family

ID=27392849

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99960363T ATE225349T1 (de) 1998-11-12 1999-11-12 Crf rezeptor-antagonisten und darauf bezogene methoden

Country Status (17)

Country Link
US (1) US6514982B1 (enExample)
EP (1) EP1129091B1 (enExample)
JP (1) JP2002529465A (enExample)
KR (1) KR20010080990A (enExample)
CN (1) CN1217945C (enExample)
AT (1) ATE225349T1 (enExample)
AU (1) AU755552B2 (enExample)
CA (1) CA2350642A1 (enExample)
DE (1) DE69903333T2 (enExample)
DK (1) DK1129091T3 (enExample)
ES (1) ES2180338T3 (enExample)
HK (1) HK1038926B (enExample)
IL (1) IL142893A0 (enExample)
NO (1) NO20012194L (enExample)
NZ (1) NZ510955A (enExample)
PT (1) PT1129091E (enExample)
WO (1) WO2000027846A2 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6531475B1 (en) * 1998-11-12 2003-03-11 Neurocrine Biosciences, Inc. CRF receptor antagonists and methods relating thereto
HK1038926B (en) * 1998-11-12 2003-07-18 Neurocrine Biosciences, Inc. Crf receptor antagonists and methods relating thereto
EP1293213A1 (en) * 2000-02-14 2003-03-19 Japan Tobacco Inc. Preventives/remedies for postoperative stress
AU2001263288A1 (en) * 2000-05-18 2001-11-26 Neurocrine Biosciences, Inc. Crf receptor antagonists
US6747034B2 (en) * 2000-11-03 2004-06-08 Neurocrine Biosciences, Inc. CRF receptor antagonists and methods relating thereto
EP1354884B1 (en) 2000-12-28 2007-10-10 Ono Pharmaceutical Co., Ltd. Cyclopenta[d]pyrazolo[1,5-a]pyrimidine compound as crf receptor antagonist
US6583143B2 (en) 2000-12-28 2003-06-24 Neurocrine Biosciences, Inc. CRF receptor antagonists and methods relating thereto
ATE320254T1 (de) * 2001-04-30 2006-04-15 Glaxo Group Ltd Crf receptor antagonisten
US7446108B2 (en) * 2001-05-21 2008-11-04 Neurocrine, Inc. Tri-and tetraaza-acenaphthylen derivatives as CRF receptor antagonists
GB0117395D0 (en) * 2001-07-17 2001-09-05 Glaxo Group Ltd Chemical compounds
US7273871B2 (en) 2001-07-17 2007-09-25 Sb Pharmco Puerto Rico Inc. Phenyl-5,6,6A,7,8,9-hexahydro-4H-1,4,9-triaza-phenalene derivatives as CRF antagonists
EP2335700A1 (en) 2001-07-25 2011-06-22 Boehringer Ingelheim (Canada) Ltd. Hepatitis C virus polymerase inhibitors with a heterobicylic structure
DE602004028820D1 (de) 2003-06-25 2010-10-07 Ono Pharmaceutical Co Methansulfonsäuresalz einer pyrazolopyrimidinverbindung, kristall davon und verfahren zu deren herstellung
US20060024661A1 (en) * 2003-07-30 2006-02-02 The Regents Of The University Of California Modulation of CRF potentiation of NMDA receptor currents via CRF receptor 2
CA2535249A1 (en) * 2003-08-12 2005-02-17 F. Hoffmann-La Roche Ag Spiro-substituted tetrahydroquinazolines as corticotropin releasing factor (cfr) antagonists
JP2007515473A (ja) * 2003-12-22 2007-06-14 エスビー・ファルムコ・プエルト・リコ・インコーポレイテッド Ｃｒｆ受容体アンタゴニストおよびそれらに関連する方法
SG184700A1 (en) 2004-02-20 2012-10-30 Boehringer Ingelheim Int Viral polymerase inhibitors
WO2005087775A1 (ja) * 2004-03-15 2005-09-22 Ono Pharmaceutical Co., Ltd. 三環式複素環化合物およびその化合物を有効成分として含有する医薬組成物
US7869958B2 (en) * 2004-08-09 2011-01-11 Research Development Foundation Structure-based modulators of B1 G-protein coupled receptors
ATE487720T1 (de) * 2007-02-01 2010-11-15 Astrazeneca Ab 5,6,7,8-tetrahydropteridin-derivate als hsp90- hemmer
EP2414359A1 (en) * 2009-03-31 2012-02-08 ArQule, Inc. Peri-fused pyrazolo-pyrimidine compounds
CA2764885C (en) 2009-06-08 2018-05-15 Takeda Pharmaceutical Company Limited Dihydropyrrolonaphtyridinone compounds as inhibitors of jak
BR112012016376A2 (pt) * 2009-12-30 2019-09-24 Arqule Inc compostos de pirrolo-aminopirimida substituída
CN113416191A (zh) * 2021-04-27 2021-09-21 西安交通大学 一种合成三环骨架2-吡啶酮/2-吡啶亚胺类化合物的方法

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4605642A (en) 1984-02-23 1986-08-12 The Salk Institute For Biological Studies CRF antagonists
US5013737A (en) * 1988-02-22 1991-05-07 American Cyanamid Company 2,4,8-Trisubstituted-3H,6H-1,4,5A,8A-tetraazaacenaphtylene-3,5-(4H)-diones and 2,4-8-trisubstituted-4,5-dihydro-5-thioxo-3H,6H-1,4,5A,8A-tetrazaacenaphthylen-3-ones
US4904658A (en) 1988-04-15 1990-02-27 American Cyanamid Company Substituted-6H,8H-pyrimido-[1,2,3-cd]purine-8,10-(9H)-diones and substituted-6H,10H-pyrimido[1,2-cd]purin-10-ones
US5063245A (en) 1990-03-28 1991-11-05 Nova Pharmaceutical Corporation Corticotropin-releasing factor antagonism compounds
FR2692893B1 (fr) 1992-06-24 1994-09-02 Sanofi Elf Dérivés alkylamino ramifiés du thiazole, leurs procédés de préparation et les compositions pharmaceutiques qui les contiennent.
TW444018B (en) * 1992-12-17 2001-07-01 Pfizer Pyrazolopyrimidines
CA2150483C (en) 1992-12-17 1999-09-14 Pfizer Limited Pyrazoles and pyrazolopyrimidines
CA2150703C (en) 1992-12-17 2002-01-08 Pfizer Limited Substituted pyrazoles
TW336932B (en) 1992-12-17 1998-07-21 Pfizer Amino-substituted pyrazoles
ES2128544T3 (es) * 1992-12-17 1999-05-16 Pfizer Pirrolopirimidinas como antagonistas del crf.
WO1995010506A1 (en) 1993-10-12 1995-04-20 The Du Pont Merck Pharmaceutical Company 1n-alkyl-n-arylpyrimidinamines and derivatives thereof
TW574214B (en) 1994-06-08 2004-02-01 Pfizer Corticotropin releasing factor antagonists
HU219911B (hu) 1994-06-16 2001-09-28 Pfizer Inc. Pirazolo-piridin-származékok, alkalmazásuk és ezeket tartalmazó gyógyászati készítmények
AU716993B2 (en) 1995-05-12 2000-03-16 Neurogen Corporation Novel deazapurine derivatives; a new class of CRF1 specific ligands
FR2735777B1 (fr) 1995-06-21 1997-09-12 Sanofi Sa Derives de 4-phenylaminothiazole, leur procede de preparation et les compositions pharmaceutiques les contenant
JP2000507552A (ja) 1996-03-26 2000-06-20 デュポン ファーマシューティカルズ カンパニー アリールオキシおよびアリールチオ縮合ピリジン、アリールオキシおよびアリールチオ縮合ピリミジン、およびそれらの誘導体
US6326368B1 (en) 1996-03-27 2001-12-04 Dupont Pharmaceuticals Company Aryloxy- and arylthiosubstituted pyrimidines and triazines and derivatives thereof
US6107300A (en) 1996-03-27 2000-08-22 Dupont Pharmaceuticals Arylamino fused pyrimidines
ZA973884B (en) 1996-05-23 1998-11-06 Du Pont Merck Pharma Tetrahydropteridines and pyridylpiperazines for treatment of neurological disorders
ES2294800T3 (es) 1996-07-24 2008-04-01 Bristol-Myers Squibb Pharma Company Azolo triazinas y pirimidinas.
AU709203B2 (en) 1996-08-06 1999-08-26 Pfizer Inc. Substituted pyrido- or pyrimido-containing 6,6- or 6,7-bicyclic derivatives
TW477787B (en) 1996-08-27 2002-03-01 Pfizer Pyrido six-membered nitrogen-containing cyclic ring derivatives having corticotropin releasing factor antagonist activity and pharmaceutical composition containing same
BR9711970A (pt) * 1996-08-28 1999-08-24 Pfizer Derivados 6,5-substitu¡do-heterobic¡clicos
ATE213495T1 (de) 1996-09-16 2002-03-15 Du Pont Pharm Co Eine resorbierbare röntgenopake markierung enthaltendes chirurgisches implantat und verfahren zum verriegeln desselben in einem körper
FR2754258B1 (fr) 1996-10-08 1998-12-31 Sanofi Sa Derives d'aminothiazole, leur procede de preparation et les compositions pharmaceutiques les contenant
US5760225A (en) 1996-11-15 1998-06-02 Neurogen Corporation Certain pyrazole derivatives as corticotropin-releasing factor receptor CRF1 specific ligands
US5723608A (en) 1996-12-31 1998-03-03 Neurogen Corporation 3-aryl substituted pyrazolo 4,3-d!pyrimidine derivatives; corticotropin-releasing factor receptor (CRF1) specific ligands
US6187777B1 (en) 1998-02-06 2001-02-13 Amgen Inc. Compounds and methods which modulate feeding behavior and related diseases
HK1038926B (en) * 1998-11-12 2003-07-18 Neurocrine Biosciences, Inc. Crf receptor antagonists and methods relating thereto

Also Published As

Publication number Publication date
CA2350642A1 (en) 2000-05-18
NO20012194D0 (no) 2001-05-03
AU755552B2 (en) 2002-12-12
DK1129091T3 (da) 2002-11-04
AU1725800A (en) 2000-05-29
HK1038926A1 (en) 2002-05-10
NZ510955A (en) 2003-01-31
WO2000027846A2 (en) 2000-05-18
KR20010080990A (ko) 2001-08-25
IL142893A0 (en) 2002-04-21
US6514982B1 (en) 2003-02-04
EP1129091A2 (en) 2001-09-05
JP2002529465A (ja) 2002-09-10
HK1038926B (en) 2003-07-18
WO2000027846A3 (en) 2000-11-16
DE69903333T2 (de) 2003-08-07
CN1217945C (zh) 2005-09-07
NO20012194L (no) 2001-05-03
CN1328559A (zh) 2001-12-26
PT1129091E (pt) 2003-02-28
EP1129091B1 (en) 2002-10-02
ES2180338T3 (es) 2003-02-01
DE69903333D1 (de) 2002-11-07

Similar Documents

Publication Publication Date Title
ATE225349T1 (de) Crf rezeptor-antagonisten und darauf bezogene methoden
DE69908173D1 (de) Crf rezeptor-antagonisten und darauf bezogene methoden
IL155702A0 (en) Piperazinylpyrazine compounds as agonist or antagonist of serotonin 5-ht2 receptor
PL360982A1 (en) Piperazinylpyrazines compounds as antagonists of serotonin 5-ht2 receptor
WO2001066534A3 (en) Cyclic and bicyclic diamino histamine-3 receptor antagonists
DK1646389T3 (da) Pyrimidin-2,4-dionderivater som gonadotropinfrigörende hormonreceptorantagonister
DE60324544D1 (de) Muskarin antagonisten
ATE430746T1 (de) Crf-rezeptor-antagonisten und zugehörige verfahren
YU39803A (sh) Jedinjenja piperazinilpirazina kao agonisti ili antagonisti serotonin 5ht-2-receptora
BRPI0417943A (pt) antagonistas de receptor de crf e métodos relacionados para essa finalidade
NO20035148D0 (no) Tri- og tetra-aza-acenaftylenderivater som CRF- reseptorantagonister
AP2001002188A0 (en) 5HT1 antagonists for antidepressant therapy.
MXPA04006571A (es) Derivado de pirimidina biciclica fusionada.
TR200101654T2 (tr) Vitronektin resept”r antagonistleri
ATE250058T1 (de) Crf rezeptor-antagonisten und darauf bezogene methoden
DE60102231D1 (de) Crf rezeptor-antagonisten und darauf bezogene methoden
EA200400822A1 (ru) Производные 3,4-дигидро-1h-изохинолин-2-ила
DE602004012318D1 (de) Crf-rezeptorantagonisten und diese betreffende verfahren

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1129091

Country of ref document: EP

REN Ceased due to non-payment of the annual fee